Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children

J Allergy Clin Immunol. 2023 Apr;151(4):832-840. doi: 10.1016/j.jaci.2023.02.003. Epub 2023 Feb 24.

Abstract

Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) pandemic, global sequencing efforts have led in the field of inborn errors of immunity, and inspired particularly by previous research on life-threatening influenza, they have revealed that known and novel inborn errors affecting type I interferon immunity underlie critical COVID-19 in up to 5% of cases. In addition, neutralizing autoantibodies against type I interferons have been identified in up to 20% of patients with critical COVID-19 who are older than 80 years and 20% of fatal cases, with a higher prevalence in men and individuals older than 70 years. Also, inborn errors impairing regulation of type I interferon responses and RNA degradation have been found as causes of multisystem inflammatory syndrome in children, a life-threatening hyperinflammatory condition complicating otherwise mild initial SARS-CoV-2 infection in children and young adults. Better understanding of these immunologic mechanisms can aid in designing treatments for severe COVID-19, multisystem inflammatory syndrome in children, long COVID, and neuro-COVID.

Keywords: COVID-19; SARS-CoV-2; multisystem inflammatory syndrome in children; type I interferon.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Intramural

MeSH terms

  • COVID-19*
  • Child
  • Humans
  • Interferon Type I*
  • Male
  • Post-Acute COVID-19 Syndrome
  • SARS-CoV-2
  • Young Adult

Substances

  • Interferon Type I

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related